Stock 1061 ESSEX BIO-TECHNOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Essex Bio-Technology Limited

Equities

1061

KYG312371035

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:17 07/05/2024 BST 		5-day change 1st Jan Change
2.48 HKD -0.80% Intraday chart for Essex Bio-Technology Limited +7.83% -0.40%
03-19 Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover MT
03-18 Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Essex Bio-Technology's Profit Jumps 22% in H1
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.
Essex Bio-Technology Limited Announces Director Changes
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022
Essex Bio-Technology Slashes Final Dividend as 2022 Profit Falls
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022, Payable on 29 June 2023
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study
Essex Bio-Technology Expects 35% Fall in 2022 Profit; Shares Slip 3%
Essex Bio-Technology Limited Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2022
Essex Bio-Technology Unit Secures Patent License from Mitotech
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1061 Stock
  4. News Essex Bio-Technology Limited
  5. Other languages